Use of MHT in Women With Cardiovascular Disease: a Systematic Review and Meta-Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/37933495/
This systematic review assesses the effect of menopausal hormone therapy (MHT) on cardiovascular outcomes and risk factors in postmenopausal women with cardiovascular disease (CVD).
No significant differences were observed between MHT users and controls regarding primary outcomes of nonfatal MI, CV-related death, or stroke. No differences in frequency of angina, HF, and TIAs were observed.
Share
Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578385/
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a modest but significant increase in serum magnesium levels.
SGLT2 inhibitors in patients with diabetes mellitus have been efficacious for glycemic control, renal protection, decreasing the risk of atherosclerotic cardiovascular disease events, and reducing cardiac mortality.
Share
Impact of SGLT2 Inhibitors on Patient Outcomes: a Network Meta-Analysis
Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-023-02035-8
A comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM), heart failure (HF), and chronic kidney...
A network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin.
Share
Kidneys in Heart Failure: Impact of Flozins and Beyond
Source : https://pubmed.ncbi.nlm.nih.gov/37937356/
Chronic kidney disease (CKD) and heart failure (HF) represent two modern epidemies and are closely related.
SGLT2 inhibitors are cardioprotective in a wide spectrum of eGFR rates, although data for patients with HF with respect to the UAC ratio remain limited.
Share
Enhanced Levels of Adiposity, Stretch and Fibrosis Markers in Patients With Coexistent Heart Failure and Atrial Fibrillation
Source : https://link.springer.com/article/10.1007/s12265-023-10454-x
The coexistence of heart failure (HF) and atrial fibrillation (AF) worsens the prognosis of patients. We aimed to study the inflammation, metabolism, adiposity, and fibrosis markers on epicardial and subcutaneous...
Plasma FABP4 was identified as the main heart failure (HF) predictor. Higher levels of adiposity markers are associated with atrial fibrillation (AF) or HF and higher stretch and fibrosis markers with combined AF and HF.
Share